Luo, Jing

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum

Diabetes Treatment and ManagementHealth disparities and outcomes

Cited by 288

Cost-Related Insulin Underuse Among Patients With Diabetes

Herkert, D., Vijayakumar, P., Luo, J., Schwartz, J. I., Rabin, T. L., DeFilippo, E., & Lipska, K. J. (2019) · JAMA Internal Medicine

Diabetes Management and EducationHealthcare Policy and Management

Cited by 230

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program

Luo, J., Feldman, R., Rothenberger, S. D., Hernandez, I., & Gellad, W. F. (2020) · JAMA Network Open

Pharmaceutical Economics and PolicyHealthcare Policy and Management

Cited by 100

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease

Luo, J., Feldman, R., Callaway Kim, K., Rothenberger, S., Korytkowski, M., Hernandez, I., & Gellad, W. F. (2023) · JAMA Network Open

Diabetes Treatment and ManagementPharmaceutical Economics and Policy

Cited by 75

Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study

White, G. E., Shu, I., Rometo, D., Arnold, J., Korytkowski, M., & Luo, J. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 66

Mental health symptoms among rural adolescents with different parental migration experiences: A cross-sectional study in China

Wang, J., Zou, J., Luo, J., Liu, H., Yang, Q., Ouyang, Y., Hu, M., & Lin, Q. (2019) · Psychiatry Research

Child and Adolescent Psychosocial and Emotional DevelopmentMental Health Treatment and Access

Cited by 42

Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System

Luo, J., Feldman, R., Rothenberger, S., Korytkowski, M., Fischer, M. A., & Gellad, W. F. (2022) · Journal of General Internal Medicine

Medication Adherence and ComplianceDiabetes Treatment and Management

Cited by 18